Correlation Between CYP2C19 Genotype, Level Of Clopidogrel Metabolite And Platelet Inhibition Status

Status

UNKNOWN

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT01210248

Enrollment

500

Registered

2010-09-28

Start date

2010-09-30

Completion date

Unknown

Last updated

2010-09-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

PRIMARY FOCUS:PATIENT THAT TAKE CLOPIDOGREL

Brief summary

The aim of this study is to check correlation between CYP2C19 genotype level of clopidogrel metabolite in plasma and platelet inhibition status.

Detailed description

THE FIRST PHASE OF THE RESEARCH WILL INVOLVE PATIENTS RECRUITMENT AND INFORMED CONSENT FOR GENETIC TESTING.THE MAJORITY OF PATIENTS WILL BE RECRUITED FROM EMERGENCY DEPARTMENT. EVERY PATIENT WILL BE ASKED ABOUT HIS AND HIS PARENT'S ETHNICITY (ASHKENASI OR SEPHARDY JEW) AND ADDITIONAL DRUGS HE TAKES. IF PATIENT AGREES TO PARTICIPATE IN THE STUDY , HIS BLOOD SAMPLE WILL BE COLLECTED FOR 3 KINDS OF TESTS: 1. GENETIC (FOR CYP450 2C19) 2. PLATELET MAPPING TEST ( BY THROMBOELASTOGRAPH ASSAY) 3. CLOPIDOGREL INACTIVE METABOLITE DETERMINATION BY CHROMATOGRAPHIC METHOD

Interventions

OTHERBLOOD COLLECTION

BLOOD SAMPLE WILL BE COLLECTED FOR 3 KINDS OF TESTS

Study design

Observational model

CASE_ONLY

Time perspective

CROSS_SECTIONAL

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* \> 18 OLD PATIENTS * THAT TAKE CLOPIDOGREL MORE THAN 1 WEEK

Exclusion criteria

* PREGNANCY * CHRONIC LIVER DISEASES

Countries

Israel

Contacts

Primary ContactADINA BAR HAIM, PhD

dinab@asaf.health.gov.il08-9779897

Backup ContactVICTORIA PAPIASHVILI, M.Sc

victoriapapi@yahoo.com0577345973

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026